ESMO publishes guidances on AI tools for clinicians, patients, and researchers Says one author: “We think there should be some degree of human oversight, otherwise, they can go completely rogue and nobody notices.”

FDA releases 10 guiding principles for AI use in drug development

FDA, in collaboration with the European Medicines Agency, has published 10 principles to help guide pharmaceutical companies using artificial intelligence to develop drug, biological, and medical devices.

OpenAI launches ChatGPT Health to analyze medical records

OpenAI has launched a ChatGPT health feature in the U.S. that is currently available only to a small group of users for refinement.

January 16, 2026

Vol.52 No.02

By Claire Marie Porter

Clinical Roundup

Mayo develops AI tool that predicts prostate cancer recurrence

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care necessary in the follow-up journey, Mayo Clinic’s Department of Radiation Oncology developed the PSA Control Tower, an intelligent monitoring tool designed to support clinicians in keeping a close, ongoing watch over patients after treatment.

January 16, 2026

Vol.52 No.02

Composite intelligence: How AI-driven biomarkers are setting the bar in immuno-oncology

Immune-checkpoint inhibitors (ICIs) transformed treatment paradigms in dozens of malignancies, yet oncologists still confront a deceptively simple question at every consult: Will this individual patient benefit and at what cost?

January 09, 2026

Vol.52 No.1

By Ofer Sharon, Michal Harel and Yehonatan Elon

Drugs & Targets

SOPHiA GENETICS partners with MD Anderson on AI-driven precision oncology

SOPHiA GENETICS and The University of Texas MD Anderson Cancer Center have entered into a collaboration to accelerate data-driven cancer care through new tools that can accurately analyze, interpret, and translate diagnostic results into clinical practice.

January 09, 2026

Vol.52 No.1

Cancer Policy

HHS issues AI strategy for internal agency operations

HHS has issued its AI strategy—“the first step” in making a “whole-of-department transformation” towards the use of artificial intelligence in public health, health care delivery, biomedical research, human services, and agency operations.

December 12, 2025

Vol.51 No.45

By Sara Willa Ernst

ESMO publishes guidances on AI tools for clinicians, patients, and researchers

Says one author: “We think there should be some degree of human oversight, otherwise, they can go completely rogue and nobody notices.”

YOU MAY BE INTERESTED IN

FDA releases 10 guiding principles for AI use in drug development

OpenAI launches ChatGPT Health to analyze medical records

Mayo develops AI tool that predicts prostate cancer recurrence

Composite intelligence: How AI-driven biomarkers are setting the bar in immuno-oncology

SOPHiA GENETICS partners with MD Anderson on AI-driven precision oncology

HHS issues AI strategy for internal agency operations

Renew today!

Subscriber content

Never miss an issue!

Login